3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
8
Thoracic
3
Gastrointestinal
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Conditions
Lymphoma
8
Lymphoma, Extranodal NK-T-Cell
6
Neoplasm Metastasis
3
Sarcoma
2
Lymphoma, Large B-Cell, Diffuse
2
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Cyclophosphamide
35
Rituximab
33
venetoclax
24
ibrutinib
14
Vincristine
14
Prednisone
14
Doxorubicin
14
Gemcitabine
13
pembrolizumab
12
fludarabine
12
Bendamustine Hydrochloride
11
Etoposide
10
obinutuzumab
9
Filgrastim
9
Dexamethasone
9
Bortezomib
9
fludarabine phosphate
8
Mycophenolic Acid
8
Drug Therapy
8
ofatumumab
7
Whole-Body Irradiation
7
Sirolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Busulfan
7
Therapeutics
6
Radiotherapy
6
Mesna
6
Lenalidomide
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
spartalizumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts